Protocols
7 protocol(s) meet the specified criteria
Drug: ARA-C
Protocol No.TitleStatus
A041501-CIRBA Phase III Trial To Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39) with Newly Diagnosed Precursor B-Cell ALLOpen
AALL1131A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsOpen
AAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
ARO-021ARO-021- Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Inducation Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid LeukemiaOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.Open
TPI-ALV-101A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Open
TPI-ALV-201A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)Open